Targets of neuroprotection in glaucoma

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


Progressive neurodegeneration of the optic nerve and the loss of retinal ganglion cells is a hallmark of glaucoma, the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma (POAG) being the most frequent form of glaucoma in the Western world. While some genetic mutations have been identified for some glaucomas, those associated with POAG are limited and for most POAG patients, the etiology is still unclear. Unfortunately, treatment of this neurodegenerative disease and other retinal degenerative diseases is lacking. For POAG, most of the treatments focus on reducing aqueous humor formation, enhancing uveoscleral or conventional outflow, or lowering intraocular pressure through surgical means. These efforts, in some cases, do not always lead to a prevention of vision loss and therefore other strategies are needed to reduce or reverse the progressive neurodegeneration. In this review, we will highlight some of the ocular pharmacological approaches that are being tested to reduce neurodegeneration and provide some form of neuroprotection.

Original languageEnglish
Pages (from-to)85-106
Number of pages22
JournalJournal of Ocular Pharmacology and Therapeutics
Issue number1-2
StatePublished - 1 Jan 2018


  • drug targets
  • glaucoma
  • neuroprotection


Dive into the research topics of 'Targets of neuroprotection in glaucoma'. Together they form a unique fingerprint.

Cite this